Active Ingredient History

  • Now
Mitemcinal is a motilin agonist derived from the macrolide antibiotic, erythromycin. It was discovered in the labs of Chugai Pharma. Mitemcinal is orally administered and it is believed to have strong promotility effects. Promotility drugs relieve symptoms of reflux by speeding the clearance of acid from the oesophagus and stomach. The parent compound, erythromycin, has these characteristics, but mitemcinal lacks the antibiotic properties of erythromycin.   Wikipedia

  • SMILES: CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C(C)C)[C@@]4(C)CC(=C(O4)[C@H](C)C(=O)[C@]1(C)OC)C
  • Mol. Mass: 755.99
  • ALogP: 4.53
  • ChEMBL Molecule:
More Chemistry
de(n-methyl)-11-deoxy-n-isopropyl-12-o-methyl-11-oxo-8,9-anhydroerythromycin a 6,9-hemiacetal fumaric acid | gm611 | gm 611 | gm-611 | mitemcinal | mitemcinal fumarate


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue